Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers

Multidisciplinary Management
BuchKartoniert, Paperback
315 Seiten
Englisch
Springererschienen am05.01.20231st ed. 2022
This book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer.mehr
Verfügbare Formate
BuchGebunden
EUR160,49
BuchKartoniert, Paperback
EUR117,69

Produkt

KlappentextThis book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer.
Zusammenfassung
Guides patient management with the most up-to-date scientific and clinical information

Stimulates investigative efforts

Written by international experts in their fields
Details
ISBN/GTIN978-3-030-80548-7
ProduktartBuch
EinbandartKartoniert, Paperback
Verlag
Erscheinungsjahr2023
Erscheinungsdatum05.01.2023
Auflage1st ed. 2022
Seiten315 Seiten
SpracheEnglisch
IllustrationenXVIII, 315 p. 29 illus., 26 illus. in color.
Artikel-Nr.51700445
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
Introduction.- State-of-the art and ongoing developments.- Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy.- Slideshow of tumor samples before and after checkpoint inhibition.- Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints.- State-of-the-art and future role of molecular biomarkers for patient selection.- Background of immunotherapy trials in prostate cancer.- Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer.- Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy.- Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC.- Benchmark of surgical safety results.- What the scientific data tell us  about predictive biomarkers of immunotherapy efficacy across the GU malignancies.- Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies.mehr

Autor

Andrea Necchi
Associate Professor, Vita-Salute San Raffaele UniversityHead of Genitourinary Medical OncologyIRCCS San Raffaele Hospital and Scientific InstituteVia Olgettina 60, 20132Milan, Italy
Philippe E. SpiessSenior Member, Department of GU OncologySenior Member, Department of Tumor BiologyAssistant Chief of Surgical ServicesMoffitt Cancer CenterProfessor, Department of UrologyUniversity of South FloridaTampa, FloridaUSA
Weitere Artikel von
Herausgegeben:Necchi, Andrea